Liquid Biopsy in Precision Medicine: Perspectives from Clinicians, Investors, and Entrepreneurs

On May 13, an offline salon on precision medicine, focusing on oncology and liquid biopsy, was held in Shanghai by Huoshu Creation. At the event, Huoshu Creation released the Global Map of Liquid Biopsy. Subsequently, Professor Qin Lunxiu, Assistant to the President and Director of the Department of Surgery at Huashan Hospital Affiliated to Fudan University, provided a detailed introduction to research on liquid biopsy and tumor metastasis and recurrence. Finally, Dr. Huang Xiao from Yunfeng Capital analyzed and introduced the precision medicine market from an investment perspective.

Global Map of Liquid Biopsy

The global map of liquid biopsy released by Huoshi Chuangzao shows that,U.S. public supports the inclusion of precision medicine in health insurance coverage, according to a survey showing that nearly2/3of the respondents believed that precision medicine testing and treatments should be covered by medical insurance. Because precision medicine and treatments are used only for a small subset of patients, they are more expensive than traditional treatments and tests. However, they offer greater value to patients and may help reduce total healthcare expenditures. Nevertheless, there remain1/3Some people believe that precision medicine has broad prospects, but healthcare costs are already high, with certain tests and treatments being prohibitively expensive. To make healthcare more affordable, health insurance companies should include precision diagnostics and therapies in their coverage.

Domestic patients with indications for liquid biopsy in542.2tens of thousands, the market size for tumor liquid biopsy is enormous, with the projected market size expected to reach216100 million. Technological breakthroughs are the prerequisite for industrial development. A comparison of scientific research between China and the United States is conducted based on the number of articles published by both countries over the years, from1977Year-on-Year2015For years, the United States has far outpaced China in this field, and there is still significant room for improvement on the technical front in China. Moreover, in recent years, both countries have shown a very clear upward trend in their achievements in this area, with experts predicting that2017The liquid biopsy field is expected to reach a tipping point in technological advancements around [year].

From a clinical perspective,CTCandctDNAIn this field, the United States stands out as a clear leader, while China is still in its early stages. With the standardization of scientific research and clinical practices, the industry is poised for better development. The government has also allocated dedicated funds to support the liquid biopsy sector. Recipients of government fund supportCTCIn the ranking of research institutions, Fudan University has applied for7topic. InctDNAfield, with the most applications submitted by Nanjing General Hospital of Nanjing Military Region of the Chinese People's Liberation Army,2topic.

Analysis of domestic and international investment and financing shows that overseas investment is more active, progresses at a faster pace, and involves larger single-round financing amounts. The total number of financing deals is75cases, primarily concentrated in the angel round, with25items. Secondly,ALunheBrounds, respectively16and14pcs.

Clinical Significance of Liquid Biopsy

Professor Qin Lunxiu stated that liquidThe advantages of biopsy are mainly reflected in simple sampling, continuous sampling and real-time monitoring, which overcome the limitations of traditional tissue biopsy, such as difficulty in obtaining tissue from some patients, clinical risks of puncture, and tumor heterogeneity.CTCThe primary significance lies in early diagnosis (early screening, risk of metastasis and recurrence), prognosis prediction (number, phenotype, dynamic changes), monitoring treatment response and prognosis, and identifying new targets for targeted therapy. From a scientific perspective, liquid biopsy enables dynamic monitoring of metastasis and represents a novel strategy against metastasis.

In Vitro Diagnostics Market Analysis

Dr. Huang Xiao introduced that in vitro diagnosticsMarket size: approximately270100 million yuan, with molecular diagnostics accounting for approximately20a market size of billions. The diagnostics sector represents a huge market, and China’s current market share is not the largest. , but it has the highest growth rate. Clinical acceptance is continuously improving; however, there is regional imbalance in the acceptance of molecular diagnostics in China, with large hospitals in coastal areas demonstrating higher adoption rates.